Company Innoviva, Inc.

INVA

US45781M1018

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 11:53:38 2024-09-11 am EDT			5-day change	1st Jan Change
19.24 ^USD	-1.26%		-2.11%	+20.17%

Jul. 31	Tranche Update on Innoviva, Inc.'s Equity Buyback Plan announced on November 9, 2022.	CI
Jul. 31	Innoviva, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI

Business description: Innoviva, Inc.

Innoviva, Inc. is a diversified holding company with a portfolio of royalties and other healthcare assets. The Company's royalty portfolio consists of respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, the Company is entitled to receive royalties from GSK on sales of RELVAR/BREO ELLIPTA. The Company's products include GIAPREZA and XERAVA. GIAPREZA (angiotensin II) injection is approved by the United States Food and Drug Administration (FDA) as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. XERAV (eravacycline) for injection is approved by the United States FDA and Singapore Health Sciences Authority (HSA) as a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections (cIAI).

Number of employees: 112

Sales by Activity: Innoviva, Inc.

Fiscal Period: December	2019	2020	2021	2022	2023
Biotechnology	261M	337M	392M	331M	310M

See all business segments

Geographical breakdown of sales: Innoviva, Inc.

Fiscal Period: December	2019	2020	2021	2022	2023
Great Britain	261M	337M	392M	312M	239M

See all geographic segments

Managers: Innoviva, Inc.

Director	Title	Age	Since
Pavel Raifeld CEO	Chief Executive Officer	40	20-05-19
Stephen Basso DFI	Director of Finance/CFO	58	23-08-20
Marianne Zhen AUD	Comptroller/Controller/Auditor	55	14-09-30

See INNOVIVA, INC. governance

Members of the board: Innoviva, Inc.

Manager	Title	Age	Since
Odysseas Kostas BRD	Director/Board Member	49	17-12-18
Jules Haimovitz BRD	Director/Board Member	73	18-02-11
Sarah Schlesinger BRD	Director/Board Member	64	18-02-11
Mark Dipaolo CHM	Chairman	53	18-02-11
Sapna R. Srivastava BRD	Director/Board Member	53	22-12-31
Derek Small BRD	Director/Board Member	48	Apr. 28

Composition of the Board of Directors

Shareholders: Innoviva, Inc.

Name	Equities	%	Valuation
BlackRock Advisors LLC 14.75 %	9,230,926	14.75 %	179 M $
Sarissa Capital Management LP 11.63 %	7,277,000	11.63 %	141 M $
Fiduciary Trust Company International 10.58 %	6,617,353	10.58 %	128 M $
Vanguard Fiduciary Trust Co. 9.879 %	6,180,450	9.879 %	120 M $
DFA Australia Ltd. 7.261 %	4,542,548	7.261 %	88 M $

List of INNOVIVA, INC. shareholders

Holdings: Innoviva, Inc.

Name	Equities	%	Valuation
ARMATA PHARMACEUTICALS, INC. 69.31%	25,076,769	69.31%	61,438,084 $

Company details: Innoviva, Inc.

Innoviva, Inc.

1350 Old Bayshore Highway Suite 400

94010, Burlingame

+650 238 9600

http://www.inva.com

Other Pharmaceuticals

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
INNOVIVA, INC.	-2.44%	-2.59%	+53.44%	+26.02%	1.22B
ELI LILLY AND COMPANY	+0.41%	-4.05%	+52.45%	+281.56%	812B
NOVO NORDISK A/S	+2.11%	-0.44%	+31.70%	+186.07%	573B
JOHNSON & JOHNSON	-1.77%	-1.43%	+1.41%	-0.51%	403B
ABBVIE INC.	-2.25%	-0.63%	+31.35%	+82.14%	352B
MERCK & CO., INC.	-0.60%	-0.91%	+5.66%	+56.81%	292B
ASTRAZENECA PLC	-0.90%	-5.69%	+17.16%	+51.94%	251B
ROCHE HOLDING AG	+0.06%	-3.19%	+6.46%	-20.88%	255B
NOVARTIS AG	-1.53%	-3.37%	+10.43%	+24.07%	236B
AMGEN INC.	-2.02%	-2.30%	+23.42%	+49.05%	177B
Average	-0.94%	-2.51%	+23.35%	+73.63%	335.3B
Weighted average by Cap.	-0.36%	-3.34%	+25.84%	+120.07%